Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Fig. 2

AZD9291 treatment inhibits colony formation and induces cell cycle arrest. a and b U87 and U251 cells were treated with different concentrations of AZD9291 for 24 h, and then changed with drug-free medium for another 12 day. The numbers of colony formation were counted. The numbers of colony formation were normalized to the control group. c and d Colony formation abilities were assessed by methylcellulose clonal assays. The number and size of clones were statistically analyzed between the control group and AZD9291 treatment group. e and g Representative data of the cell cycle analysis of AZD9291-treated cells. U87 and U251 cells were treated with AZD9291 at the indicated concentrations for 24 h. Cell cycle profile was evaluated using flow cytometry. f and h Quantitative analysis of cell cycle phase distribution in the control group and the AZD9291-treated group. The data from three independent experiments were expressed as the means ± SEM (*P < 0.05)

Back to article page